In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%.

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating ...

B iogen Inc. (BIIB) closed at $217.56 in the latest trading session, marking a +0.15% move from the prior day. The stock lagged the S&P 500's daily gain of 0.51%. Elsewhere, the Dow gained 0.2% ...

Is Eli Lilly stock a buy or a sell? In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.

The latest trading session saw Biogen Inc. (BIIB) ending at $217.23, denoting a -1.71% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a loss of 1.02% ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report ... Mizuho Securities also maintained a Buy rating on the stock with a $277.00 price target.

Is Eli Lilly stock a buy? Biogen Inc. (BIIB) concluded the recent trading session at $221.74, signifying a -0.98% move from its prior day's close.

In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%. Meanwhile, ...

Biogen Inc. (BIIB) closed at $217.56 in the latest trading session, marking a +0.15% move from the prior day. Owens Corning (OC) Laps the Stock Market: Here's Why New data from the RESPOND study ...